Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension of COURAGE-ALS (CY 5032)
2021-004727-33Phase 3Terminated
- Sponsor
- Cytokinetics
- Start
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of reldesemtiv in amyotrophic lateral sclerosis (ALS), sponsored by Cytokinetics. Primary endpoint: Incidence of adverse events. Started Aug 2022; status: terminated.
02
Drugs
reldesemtiv
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on 2021-004727-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-004727-33.